Evidence map›Paper›PMID 36135358›Full record

ArticleeLife2022

SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study.

Carlos A Prete, Lewis F Buss, Charles Whittaker, Tassila Salomon, Marcio K Oikawa, Rafael H M Pereira, Isabel C G Moura, Lucas Delerino, Manoel Barral-Netto, Natalia M Tavares and 35 more

Abstract read
In one paragraph

Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

Carlos A Prete *Department of Electronic Systems Engineering, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-3907-423X
Lewis F Buss *Imperial College London, London, United Kingdom.
Charles Whittaker *MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom.
Tassila Salomon *Faculdade Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil.
Marcio K OikawaUniversidade Federal do ABC, São Bernardo do Campo, Brazil.
Rafael H M PereiraInstitute for Applied Economic Research (Ipea), Brasília, Brazil.
Isabel C G MouraFaculdade Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil.
Lucas DelerinoFundação Oswaldo Cruz, Manguinhos, Brazil.
Manoel Barral-NettoFundação Oswaldo Cruz, Manguinhos, Brazil.ORCID 0000-0002-5823-7903
Natalia M TavaresFundação Oswaldo Cruz, Manguinhos, Brazil.
Rafael F O FrancaFundação Oswaldo Cruz, Manguinhos, Brazil.
Viviane S BoaventuraFundação Oswaldo Cruz, Manguinhos, Brazil.
Fabio MiyajimaFundação Oswaldo Cruz, Manguinhos, Brazil.
Alfredo Mendrone-JuniorFundação Pró Sangue Hemocentro de São Paulo (FPS), São Paulo, Brazil.
Cesar de Almeida-NetoFundação Pró Sangue Hemocentro de São Paulo (FPS), São Paulo, Brazil.ORCID 0000-0002-8490-4634
Nanci A SallesFundação Pró Sangue Hemocentro de São Paulo (FPS), São Paulo, Brazil.
Suzete C FerreiraFundação Pró Sangue Hemocentro de São Paulo (FPS), São Paulo, Brazil.
Karine A FladzinskiCentro de Hematologia e Hemoterapia do Paraná (HEMEPAR), Curitiba, Brazil.
Luana M de SouzaCentro de Hematologia e Hemoterapia do Paraná (HEMEPAR), Curitiba, Brazil.
Luciane K SchierCentro de Hematologia e Hemoterapia do Paraná (HEMEPAR), Curitiba, Brazil.
Patricia M InoueCentro de Hematologia e Hemoterapia do Paraná (HEMEPAR), Curitiba, Brazil.
Lilyane A XabregasFundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, Brazil.
Myuki A E CrispimFundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, Brazil.
Nelson FraijiFundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, Brazil.
Fernando L V AraujoFundação de Hematologia e Hemoterapia da Bahia (HEMOBA), Salvador, Brazil.
Luciana M B CarlosCentro de Hematologia e Hemoterapia do Ceará (HEMOCE), Fortaleza, Brazil.
Veridiana PessoaCentro de Hematologia e Hemoterapia do Ceará (HEMOCE), Fortaleza, Brazil.
Maisa A RibeiroFundação HEMOMINAS, Belo Horizotne, Brazil.
Rosenvaldo E de SouzaFundação HEMOMINAS, Belo Horizotne, Brazil.
Sônia M N da SilvaFundação HEMOMINAS, Belo Horizotne, Brazil.
Anna F CavalcanteFundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, Brazil.
Maria I B ValençaFundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, Brazil.
Maria V da SilvaFundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, Brazil.
Esther LopesInstituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro, Brazil.
Luiz A FilhoInstituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro, Brazil.
Sheila O G MateosInstituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro, Brazil.ORCID 0000-0001-5416-2724
Gabrielle T NunesFundação Oswaldo Cruz, Manguinhos, Brazil.
Alexander L Silva-JuniorFundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, Brazil.
Michael P BuschVitalant Research Institute, San Franscico, United States.
Marcia C CastroHarvard TH Chan School of Public Health, Boston, United States.
Christopher DyeDepartment of Zoology, University of Oxford, Oxford, United Kingdom.
Oliver RatmannImperial College London, London, United Kingdom.ORCID 0000-0001-8667-4118
Nuno R FariaMRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom.
Vítor H NascimentoDepartment of Electronic Systems Engineering, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-0543-4735
Ester C SabinoInstituto de Medicina Tropical, University of São Paulo, São Paulo, Brazil.ORCID 0000-0003-2623-5126

Funding

Medical Research Council MR/R015600/1Medical Research Council MR/S0195/1Medical Research Council MR/S019510/1Medical Research Council MR/V038109/1NHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007IWellcome TrustWellcome Trust 204311/Z/16/Z
6 · The paper itself

Abstract

Background: The COVID-19 situation in Brazil is complex due to large differences in the shape and size of regional epidemics. Understanding these patterns is crucial to understand future outbreaks of SARS-CoV-2 or other respiratory pathogens in the country. Methods: We tested 97,950 blood donation samples for IgG antibodies from March 2020 to March 2021 in 8 of Brazil's most populous cities. Residential postal codes were used to obtain representative samples. Weekly age- and sex-specific seroprevalence were estimated by correcting the crude seroprevalence by test sensitivity, specificity, and antibody waning. Results: The inferred attack rate of SARS-CoV-2 in December 2020, before the Gamma variant of concern (VOC) was dominant, ranged from 19.3% (95% credible interval [CrI] 17.5-21.2%) in Curitiba to 75.0% (95% CrI 70.8-80.3%) in Manaus. Seroprevalence was consistently smaller in women and donors older than 55 years. The age-specific infection fatality rate (IFR) differed between cities and consistently increased with age. The infection hospitalisation rate increased significantly during the Gamma-dominated second wave in Manaus, suggesting increased morbidity of the Gamma VOC compared to previous variants circulating in Manaus. The higher disease penetrance associated with the health system's collapse increased the overall IFR by a minimum factor of 2.91 (95% CrI 2.43-3.53). Conclusions: These results highlight the utility of blood donor serosurveillance to track epidemic maturity and demonstrate demographic and spatial heterogeneity in SARS-CoV-2 spread. Funding: This work was supported by Itaú Unibanco 'Todos pela Saude' program; FAPESP (grants 18/14389-0, 2019/21585-0); Wellcome Trust and Royal Society Sir Henry Dale Fellowship 204311/Z/16/Z; the Gates Foundation (INV- 034540 and INV-034652); REDS-IV-P (grant HHSN268201100007I); the UK Medical Research Council (MR/S0195/1, MR/V038109/1); CAPES; CNPq (304714/2018-6); Fundação Faculdade de Medicina; Programa Inova Fiocruz-CE/Funcap - Edital 01/2020 Number: FIO-0167-00065.01.00/20 SPU N°06531047/2020; JBS - Fazer o bem faz bem.

Indexed as

COVID-19Antibodies, ViralBlood DonorsBrazilCross-Sectional StudiesFemaleHumansImmunoglobulin GMaleSARS-CoV-2Seroepidemiologic StudiesAntibodies, ViralImmunoglobulin Gattack rateblood donorsCOVID-19epidemiologyglobal healthinfection fatality rateSARS-CoV-2serosurveillanceviruses

Identifiers

PMID36135358
PMCPMC9545556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.